| M-118, a novel, low-molecular-weight heparin for the potential treatment of cardiovascular disorders. | |
| | |
MedLine Citation:
|
PMID: 20730701 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Safe inhibition of thrombosis is a key therapeutic strategy in modern cardiovascular medicine, and both unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are commonly used in clinical practice. However, both have several drawbacks, such as the unpredictable pharmacokinetics of UFH and the non-reversibility of LMWH. M-118, being developed by Momenta Pharmaceuticals Inc, is a novel LMWH that has been engineered to overcome the drawbacks of UFH and currently available LMWHs, while maintaining their beneficial attributes. In preclinical studies and phase I clinical trials, M-118 demonstrated potent activity against thrombin and Factor Xa, which could be reversed with protamine; M-118 also demonstrated a high and predictable bioavailability, and a short half-life. Promising results were observed in a phase II clinical trial in patients undergoing coronary interventions, although phase III clinical trials are required to establish the role for M-118 in contemporary medicine. |
| | |
Authors:
|
Hriday Shah; Hitinder S Gurm |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Current opinion in investigational drugs (London, England : 2000) Volume: 11 ISSN: 2040-3429 ISO Abbreviation: Curr Opin Investig Drugs Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-08-23 Completed Date: 2011-02-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100965718 Medline TA: Curr Opin Investig Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 1059-65 Citation Subset: IM |
Affiliation:
|
University of Michigan, Division of Cardiovascular Medicine, 2A394, 1500 East Medical Center Drive, Ann Arbor, MI 48109-5853, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Anticoagulants / adverse effects, pharmacokinetics, pharmacology, therapeutic use Cardiovascular Diseases / drug therapy* Clinical Trials as Topic Dogs Drug Evaluation, Preclinical Heparin, Low-Molecular-Weight / adverse effects, pharmacokinetics, pharmacology, therapeutic use* Humans Male Mice Mice, Knockout Rabbits Rats Thrombin / antagonists & inhibitors Thrombosis / drug therapy |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/Heparin, Low-Molecular-Weight; 0/M-118 compound; EC 3.4.21.5/Thrombin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for t...
Next Document: Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pu...